Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.63 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094083 | 1.00 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2MAPTCNR2 | |
| SCHEMBL333717 | 0.92 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTCNR2 | |
| SCHEMBL1094987 | 0.84 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MAPTMITF | |
| SCHEMBL1094984 | 0.84 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MAPTMITF | |
| SCHEMBL1095922 | 0.84 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2MAPTMITF | |
| SCHEMBL1095926 | 0.84 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2MAPTMITF | |
| SCHEMBL334276 | 0.84 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2MAPTCNR2 | |
| SCHEMBL334720 | 0.81 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTCNR2 | |
| SCHEMBL29293351 | 0.81 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTCNR2 | |
| SCHEMBL9030935 | 0.81 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580968-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153813-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBOTT LABORATORIES (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2237779-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009085945-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | NPC1 2712/4885RAB9A 4401/4885SMN1; SMN2 4187/4885 |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | NPC1 2712/4885RAB9A 4401/4885SMN1; SMN2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.